These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33199881)

  • 61. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.
    Omboni S; Malacco E; Mallion JM; Volpe M
    Drugs Aging; 2012 Dec; 29(12):981-92. PubMed ID: 23179896
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
    Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
    J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data.
    Pilz S; Trummer C; Verheyen N; Schwetz V; Pandis M; Aberer F; Grübler MR; Meinitzer A; Bachmann A; Voelkl J; Alesutan I; Catena C; Sechi LA; März W; Obermayer-Pietsch B; Tomaschitz A
    Horm Metab Res; 2018 May; 50(5):375-382. PubMed ID: 29723896
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Front Endocrinol (Lausanne); 2021; 12():625457. PubMed ID: 33841329
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Association of Antihypertensive Effects of Esaxerenone with the Internal Sodium Balance in Dahl Salt-Sensitive Hypertensive Rats.
    Hattori M; Rahman A; Kidoguchi S; Jahan N; Fujisawa Y; Morisawa N; Ohsaki H; Kobara H; Masaki T; Hossain A; Steeve A; Nishiyama A
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012182
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cochrane in context: pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
    Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers.
    Tezuka Y; Ito S
    Curr Hypertens Rep; 2022 Jul; 24(7):215-224. PubMed ID: 35488944
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study.
    Kang SM; Youn JC; Chae SC; Park CG; Yang JY; Kim MH; Hong TJ; Kim CH; Kim JJ; Shin DG; Jeong JW; Yoon JH; Park SH; Kwon J; Cho SY
    Clin Ther; 2011 Dec; 33(12):1953-63. PubMed ID: 22136978
    [TBL] [Abstract][Full Text] [Related]  

  • 71. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
    Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
    Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
    Tytus RH; Burgess ED; Assouline L; Vanjaka A
    Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
    Burgess ED; Lacourcière Y; Ruilope-Urioste LM; Oparil S; Kleiman JH; Krause S; Roniker B; Maurath C
    Clin Ther; 2003 Sep; 25(9):2388-404. PubMed ID: 14604739
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of esaxerenone, a nonsteroidal mineralocorticoid receptor blocker, independent of urinary sodium/potassium ratio and salt intake.
    Morimoto S; Ichihara A
    Hypertens Res; 2024 Apr; 47(4):970-971. PubMed ID: 38273001
    [No Abstract]   [Full Text] [Related]  

  • 75. A randomized, open-label, dose-response study of losartan in hypertensive children.
    Webb NJ; Wells TG; Shahinfar S; Massaad R; Dankner WM; Lam C; Santoro EP; McCrary Sisk C; Blaustein RO
    Clin J Am Soc Nephrol; 2014 Aug; 9(8):1441-8. PubMed ID: 24875194
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Antihypertensive efficacy of indapamide SR in hypertensive patients uncontrolled with a background therapy: the NATIVE study.
    Akram J; Sheikh UE; Mahmood M; Donnelly R
    Curr Med Res Opin; 2007 Dec; 23(12):2929-36. PubMed ID: 17931463
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.
    Fukui T; Rahman M; Hayashi K; Takeda K; Higaki J; Sato T; Fukushima M; Sakamoto J; Morita S; Ogihara T; Fukiyama K; Fujishima M; Saruta T;
    Hypertens Res; 2003 Dec; 26(12):979-90. PubMed ID: 14717341
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial.
    Derosa G; Maffioli P; D'Avino M; Sala C; Mugellini A; Vulpis V; Felis S; Guasti L; Sarzani R; Bestetti A; Vanasia M; Gaudio G;
    Cardiovasc Ther; 2017 Feb; 35(1):47-54. PubMed ID: 27860389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.